DE69928677D1 - Grf-analoge mit erhöhter biologischer potenz - Google Patents

Grf-analoge mit erhöhter biologischer potenz

Info

Publication number
DE69928677D1
DE69928677D1 DE69928677T DE69928677T DE69928677D1 DE 69928677 D1 DE69928677 D1 DE 69928677D1 DE 69928677 T DE69928677 T DE 69928677T DE 69928677 T DE69928677 T DE 69928677T DE 69928677 D1 DE69928677 D1 DE 69928677D1
Authority
DE
Germany
Prior art keywords
grf
grf analogs
increased biological
analogs
biological potential
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69928677T
Other languages
English (en)
Inventor
Denis Gravel
Abdelkrim Habi
Paul Brazeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theratechnologies Inc
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/148,982 external-priority patent/US6020311A/en
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Application granted granted Critical
Publication of DE69928677D1 publication Critical patent/DE69928677D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69928677T 1998-09-08 1999-09-07 Grf-analoge mit erhöhter biologischer potenz Expired - Lifetime DE69928677D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/148,982 US6020311A (en) 1995-05-26 1998-09-08 GRF analogs with increased biological potency
US09/389,486 US6458764B1 (en) 1995-05-26 1999-09-03 GRF analogs with increased biological potency
PCT/CA1999/000816 WO2000014236A2 (en) 1998-09-08 1999-09-07 Grf analogs with increased biological potency

Publications (1)

Publication Number Publication Date
DE69928677D1 true DE69928677D1 (de) 2006-01-05

Family

ID=26846360

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69928677T Expired - Lifetime DE69928677D1 (de) 1998-09-08 1999-09-07 Grf-analoge mit erhöhter biologischer potenz
DE1109909T Pending DE1109909T1 (de) 1998-09-08 1999-09-07 Grf-analoge mit erhöhter biologischer potenz

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE1109909T Pending DE1109909T1 (de) 1998-09-08 1999-09-07 Grf-analoge mit erhöhter biologischer potenz

Country Status (12)

Country Link
US (2) US6458764B1 (de)
EP (1) EP1109909B1 (de)
JP (1) JP2002524472A (de)
KR (1) KR100474868B1 (de)
AT (1) ATE311453T1 (de)
AU (1) AU755852B2 (de)
BR (1) BR9913515A (de)
CA (1) CA2342070A1 (de)
DE (2) DE69928677D1 (de)
ES (1) ES2164626T1 (de)
MX (1) MXPA01002468A (de)
WO (1) WO2000014236A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458764B1 (en) * 1995-05-26 2002-10-01 Theratechnologies Inc. GRF analogs with increased biological potency
EP1305338A2 (de) * 2000-08-02 2003-05-02 Theratechnologies Inc. Modifizierte peptide mit erhöhter wirksamkeit
CA2496687A1 (en) * 2002-09-18 2004-04-01 Centre Hospitalier De L'universite De Montreal (Chum) Ghrh analogues
ES2320754T3 (es) * 2002-10-22 2009-05-28 Waratah Pharmaceuticals, Inc. Tratamiento de la diabetes.
EP1628676A1 (de) 2003-05-29 2006-03-01 Theratechnologies Inc. Zusammesetzungen mit grf-analogen und ihre verwendung
US20070155698A1 (en) * 2003-09-02 2007-07-05 Doron Steinberg Oxazaborolidines as bacteria effectors
JP4726797B2 (ja) * 2003-10-20 2011-07-20 セラテクノロジーズ・インコーポレーテッド 消耗症に罹患している患者の治療における成長ホルモン放出因子類似体の使用
KR101228229B1 (ko) * 2004-10-20 2013-01-31 쎄러테크놀로지스 인코포레이티드 성장 호르몬 분비 촉진물질 및 그의 용도
PT1869066E (pt) * 2005-04-08 2010-02-03 Lonza Ag Síntese de peptídeo de hélice-alfa sobre resina peg
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
ES2610531T3 (es) 2007-03-28 2017-04-28 President And Fellows Of Harvard College Polipéptidos cosidos
WO2011153491A2 (en) 2010-06-03 2011-12-08 University Of Miami Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
RU2639523C2 (ru) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы и их применение
US9079974B2 (en) 2011-12-21 2015-07-14 The University Of Miami GH-RH analogs with potent agonistic effects
JP6450192B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス，インコーポレイテッド トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物
MX362492B (es) 2012-02-15 2019-01-21 Aileron Therapeutics Inc Macrociclos peptidomiméticos.
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
WO2014100809A2 (en) 2012-12-21 2014-06-26 University Of Miami Ghrh agonists for the treatment of ischemic disorders
EP2935317B1 (de) 2012-12-21 2019-03-27 University of Miami Ghrh-agonisten zur inselzelltransplantation und -funktion und zur behandlung von diabetes
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
EP3294318A4 (de) 2015-03-20 2019-04-03 Aileron Therapeutics, Inc. Peptidomimetische makrozyklen und verwendungen davon
EP4380598A2 (de) * 2021-08-06 2024-06-12 Rebalance Health, Inc. Wachstumshormon freisetzende hormonpeptide und formulierungen davon

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914189A (en) * 1987-02-05 1990-04-03 The Adminstrators Of The Tulane Educational Fund Synthetic GHRH analogs
US5112808A (en) * 1987-05-11 1992-05-12 American Cyanamid Company Alkylated hormone-releasing peptides and method of treatig mammals therewith
WO1991016923A1 (en) * 1990-05-04 1991-11-14 The Administrators Of The Tulane University Educational Fund Novel synthetic grf analogs
US6020311A (en) * 1995-05-26 2000-02-01 Theratechnologies, Inc. GRF analogs with increased biological potency
US6458764B1 (en) * 1995-05-26 2002-10-01 Theratechnologies Inc. GRF analogs with increased biological potency
BRPI9608799B8 (pt) * 1995-05-26 2019-11-05 Theratechnologies Inc análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica.

Also Published As

Publication number Publication date
WO2000014236A3 (en) 2000-06-02
ATE311453T1 (de) 2005-12-15
CA2342070A1 (en) 2000-03-16
WO2000014236A2 (en) 2000-03-16
DE1109909T1 (de) 2002-05-23
AU5500799A (en) 2000-03-27
ES2164626T1 (es) 2002-03-01
KR20010086368A (ko) 2001-09-10
EP1109909A2 (de) 2001-06-27
KR100474868B1 (ko) 2005-03-08
BR9913515A (pt) 2001-06-05
US6458764B1 (en) 2002-10-01
JP2002524472A (ja) 2002-08-06
MXPA01002468A (es) 2002-04-24
AU755852B2 (en) 2002-12-19
EP1109909B1 (de) 2005-11-30
US20040171534A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
DK0828758T3 (da) Kimæriske fedtlegeme-pro-GRF-analoger med forøget biologisk potensering
DE69928677D1 (de) Grf-analoge mit erhöhter biologischer potenz
IL129126A0 (en) Monocyclic l-nucleosides analogs and uses thereof
ATE494902T1 (de) Ein huhn gnrh-ii analog zur verwendung in der reduktion des tumorzellwachstums
ATE76296T1 (de) Pharmazeutische zusammensetzung zur behandlung von akuter myocardischer ischaemie.
ES2124263T3 (es) Peptidos con una actividad de liberacion de hormonas de crecimiento.
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
DE60041976D1 (de) Phenoxycarbonsäureverbindungen und zusammensetzungen zur verabreichung aktiver wirkstoffe
GT199800085A (es) Sal tartrato de un dipeptido sustituido.
AT389445B (de) Orale zubereitung, insbesondere zur bekaempfung von mundgeruch
TR200201920T2 (tr) İntegrinlerin reseptörlerine bağlanmasını engelleyen karboksilik asit türevleri.
FR2591485B1 (fr) Compositions stabilisees contenant l'activateur du plasminogene du tissu humain.
DE68909409D1 (de) Heilmitteldosierung zur verabreichung an fische.
GR3023038T3 (en) Use of coconut precursor fatty acid as insect-repellent.
BR0304298A (pt) Composição contendo um ácido orgânico cosmeticamente ativo e um produto de legume
ES8700054A1 (es) Procedimiento de obtencion de germicidas a base de acidos clorhidrico y fosforico.
TW371630B (en) Deodorizer
ES2040240T3 (es) Agente citostatico de platino.
UA19786A (uk) Засіб для обробки бульб кортоплі перед посадкою
ATE39697T1 (de) Erythromycin-a-salz mit mucosecretolytischer und fluidisierender aktivitaet, verfahren zu seiner herstellung und dieses enthaltende pharmazeutische zusammensetzungen.
RU2000121700A (ru) Способ лечения остеохондропатий
UA37442A (uk) Спосіб впливу на фолікулогенез яєчників самиць
HUT47377A (en) Insecticide-granulate with increased biological effect containing as active substance carbofuran
ECSP972038A (es) Fomento del crecimiento de pollos

Legal Events

Date Code Title Description
8332 No legal effect for de